Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
April 2018
-
Media ReleaseAveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of NeurologyIncludes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a…
-
Key ReleaseNovartis appoints John Tsai Head of Global Drug Development and Chief Medical OfficerBasel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and…
-
Media ReleaseNovartis delivered a strong first quarter and acted to become a more focused medicines companyNet sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong…
-
Media ReleaseNovartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicamentsHausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto, qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le…
-
Media ReleaseNovartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werdenDer Nettoumsatz steigt um 4% (kWk[1], +10% USD), vor allem dank folgender Beiträge: Entresto wächst um 126% (kWk) auf USD 200 Millionen, da es weltweit vermehrt eingesetzt wird Cosentyx legt um…
-
Media ReleaseSandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disordersDeal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
-
Media ReleaseNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failuresThe LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials …
-
Media ReleaseNovartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarialsCompany to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
-
Media ReleaseNovartis bekräftigt Engagement zur Eliminierung von Malaria und investiert USD 100 Millionen in die Erforschung und Entwicklung der nächsten Generation von MalariamedikamentenDas Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau…
-
Media ReleaseNovartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle générationL'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'…
-
Key ReleaseNovartis tender offer for AveXis commencesBasel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
-
Media ReleaseNovartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetesHeart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
Pagination
- ‹ Previous page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- …
- 100
- › Next page